Conference Coverage (ASM)

Vaccine Targets Vancomycin-Resistant Bacteria

Published in Transplant Weekly, May 11th, 1998

Antibodies to a new vaccine antigen protected mice against challenge with a clinical isolate of a vancomycin-resistant bacterium.

Vancomycin is the last line of defense against organisms that have acquired resistance to antimicrobial drugs. Species of Enterococcus faecalis - which occur among the normal intestinal flora of humans - are a major cause of urinary tract infections, wound infections, intra-abdominal abscesses, endocarditis, bacteremia, and many hospital-acquired infections including bacterial sepsis of newborns. An increasing number of these infections are caused by enterococci that have developed resistance to vancomycin.

Early...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Transplant Weekly

Source: Transplant Weekly (1998-05-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry